ADUS
$101.52
Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States.
Intraday
Recent News
Addus HomeCare Details 2026 Priorities as Medicaid Redeterminations Ease at KeyBanc Forum
Addus HomeCare (NASDAQ:ADUS) executives used a fireside chat at KeyBanc’s Healthcare Forum to outline operational priorities for 2026, discuss the pace of personal care census recovery after Medicaid redeterminations, and address the policy backdrop around Medicaid funding and oversight. 2025 focus
4 Outpatient Home Health Stocks Gaining Attention Amid Market Shifts
An aging population and rising AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, OPCH and ADUS stand to benefit.
Addus HomeCare Says Q4 Ended Strong, Sees Solid Q1 Start Despite Weather, Holiday Disruptions
Addus HomeCare (NASDAQ:ADUS) executives said the company exited the fourth quarter in “really good shape,” citing a strong earnings quarter and what they described as a solid start to the first quarter, despite typical holiday-season scheduling pressures and weather-related disruptions early in the
Q4 Earnings Roundup: Addus HomeCare (NASDAQ:ADUS) And The Rest Of The Senior Health, Home Health & Hospice Segment
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Addus HomeCare (NASDAQ:ADUS) and the best and worst performers in the senior health, home health & hospice industry.
Addus HomeCare CFO Flags Medicaid Rate Outlook, Gentiva Deal Progress, and M&A Pipeline at Conference
Addus HomeCare (NASDAQ:ADUS) CFO Brian Poff discussed the company’s strategy, Medicaid rate environment, compliance posture, and recent operating trends in a wide-ranging conversation that also touched on M&A priorities and growth initiatives in personal care and hospice. From a pure-play perso